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EKSTRAK DAN SEBATIAN AKTIF 
ANDROGRAPHIS PANICULATA DAN CURCUMA XANTHORRHIZA 
MERENCAT GLUKURONIDASI MORFINA 
 
ABSTRAK 
 
Baru-baru ini, fenomena interaksi herba-drug telah mendapat perhatian hampir 
seantero dunia atas sebab tersebarnya populariti penggunaan produk herba dalam bentuk 
suplemen tambahan. Dalam kajian ini kesan perencatan herba Malaysia yang telah 
disenaraikan iaitu: hempedu bumi (Andrographis paniculata) dan temulawak (Curcuma 
xanthorrhiza) terhadap proses glukuronidasi morfina akan diuji menggunakan model protein 
rekombinan UGT2B7 dan mikrosom hepar bersumberkan dari manusia. Kesemua ekstrak 
etanol dan akueus bagi herba hempedu bumi serta andrografolida telah merencatkan aktiviti 
glukuronidasi morfina kecuali neoandrografolida. Ekstrak akueus merencatkan glukuronidasi 
morfina secara sederhana jika dibandingkan dengan ekstrak etanol dan andrografolida. 
Andrografolida adalah fito-konstituen yang dipercayai telah menyumbang besar terhadap 
trend perencatan yang ditunjukkan oleh ekstrak etanol dan analisis kinetik menunjukkan 
bahawa kedua-dua ekstrak etanol dan andrografolida merencatkan proses glukuronidasi 
morfina secara kompetitif (bukan tulen) dengan julat pemalar-perencatan, Kic dari 3.22 
hingga 17.94 µg/mL bagi ekstrak etanol dan juga dari 1.35 hingga 15.06 µM bagi 
andrografolida yang mana kesemuanya dikaji di dalam protein rekombinan dan mikrosom 
hepar. Sementara itu, ekstrak akueus temulawak didapati tidak mampu merencatkan proses 
glukuronidasi morfina sekuat ekstrak etanol. Kurkumin pula tidak memberikan sebarang 
kesan terhadap glukuronidasi morfina manakala xantorhizol merencatkan proses 
glukuronidasi morfina secara sederhana dalam model protein rekombinan dan mikrosom 
hepar. Analisis kinetik terhadap xantorhizol menunjukkan bahawa fito-konstituen ini 
merencatkan glukuronidasi morfina secara kompetitif (sebahagiannya kompetitif tulen dan 
selebih nya kompetitif bukan tulen) dengan julat pemalar-perencatan, Kic dari 1.07 hingga 
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116.74 µM manakala ekstrak etanol merencatkan proses glukuronidasi morfina melalui 
beberapa laluan mekanisme (kompetitif tulen, kompetitif bukan tulen dan bukan kompetitif) 
dengan julat pemalar-perencatan, Kic dari 3.22 hingga 14.30 µg/mL dalam model protein 
rekombinan dan mikrosom hepar. Maklumat dari kajian ini dipercayai dapat 
menyumbangkan informasi tambahan terhadap mana-mana para penyelidik yang ingin 
meneruskan kajian ini ke tahap klinikal dan juga ahli-ahli pengamal perubatan yang sering 
kali berhadapan terhadap pesakit yang dibekalkan dengan preskripsi morfina. 
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ANDROGRAPHIS PANICULATA AND CURCUMA XANTHORRHIZA 
EXTRACTS AND ACTIVE CONSTITUENTS INHIBIT 
MORPHINE GLUCURONIDATION 
 
ABSTRACT 
 
A resurgence in the widespread popularity of herbal product in its supplement forms 
has recently attracted global attention concerning to herb-drug interaction. The inhibitory 
effects of selected Malaysian medicinal plant herbs namely Andrographis paniculata and 
Curcuma xanthorrhiza on morphine glucuronidation were evaluated on recombinant 
UGT2B7 protein and human liver microsomes. Ethanolic and aqueous extracts of 
Andrographis paniculata as well as andrographolide inhibited morphine glucuronidation at 
various degrees except for neoandrographolide. Aqueous extract moderately inhibited 
morphine glucuronidation compared to andrographolide and ethanolic extract. 
Andrographolide is the main perpetrator that contributes to the potent inhibitory action of 
ethanolic extract and kinetic analysis has suggested that andrographolide and Andrographis 
paniculata ethanolic extract competitively (mixed competitive) inhibited morphine 
glucuronidation featuring competitive inhibition constant, Kic values ranging from 1.35 to 
15.06 µM for andrographolide and 3.22 to 17.94 µg/mL for Andrographis paniculata 
ethanolic extract on both recombinant UGT2B7 protein and human liver microsomes. 
Meanwhile, ethanolic extract of Curcuma xanthorrhiza strongly inhibited morphine 
glucuronidation while that of aqueous extract had displayed moderate inhibition trend on 
both recombinant UGT2B7 protein and human liver microsomes. Xanthorrhizol inhibited 
morphine metabolism not as potent as ethanolic extract whereas curcumin did not pose any 
significant inhibitory trend on morphine glucuronidation. Kinetic assessment has shown that 
xanthorrhizol competitively (pure and mixed competitive) inhibited morphine 
glucuronidation with Kic values ranging from 1.07 to 116.74 µM whereby Curcuma 
xanthorrhiza ethanolic extract inhibited morphine glucuronidation through various modes of 
xxvi 
 
inhibition (pure competitive, mixed competitive and non-competitive) with Kic values 
ranging from 3.22 up to 14.30 µg/mL on both recombinant UGT2B7 protein and human liver 
microsomes. Data generated from this study is expected to provide supplementary 
information particularly for researchers with intention to conduct clinical study in humans 
and for the clinicians who routinely deal with patients that are prescribed with morphine. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Background and Highlights 
The use of herbal medicines to treat ailments has been part of mankind’s attempt to escape 
from sicknesses for millennia. As science ascended after the 17
th
 century, the arcane natures 
of herbal medicines were progressively demystified. Isolation of bioactive chemical species 
from these herbs became popular and since then, the practice of medicines derived from 
plant sources have become common in many clinical settings even until today (Solecki 
1975). 
 
However, the 1990’s had witnessed an outbreak on the market sales of herbal medicines in 
‘supplement’ form which can simply be obtained anywhere or by anyone (Bernard 2005). 
The word ‘supplement’ can be interpreted as a blanket term used to promote the practice of 
alternative medicine through their ‘all-natural’ claim. This marketing tactic masks the fact 
that these natural supplements are actually a hotchpotch of potentially biological active 
compounds that present in the supplement’s capsule in unknown quantities. What is worst, 
these supplements flooded the market and are produced without proper scrutiny from 
relevant authorities. 
 
On the other hand, it is an undeniable fact that most people nowadays chose to prescribe 
conventional drugs (e.g. paracetamol) even for treating a headache. When the prescription of 
conventional drugs combine with the spate of herbal supplement consumptions, the 
possibility of overlapping between the two will exist. This condition is known as herb-drug 
interaction and can occur to numerous combinations between herbs and conventional drugs 
which result to the alteration of drug efficacies that may lead to overdosing or underdosing 
of the prescribed drug. 
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This has come to a realization where scientific investigations need to be carried out 
concerning to the effects of herbal supplements on metabolic process of conventional drugs. 
In the last decade, interests in studying the involvement of drug metabolizing enzymes on 
metabolic interaction between herbal supplement and conventional drugs have grown 
significantly. The number of publications citing herb-drug interactions have increased by 
nearly five-fold in the 2000’s compared to 1990’s (Mohamed 2010).  
 
Cytochrome P450 and UGT enzymes are reputed to be the most important species of drug 
metabolizing enzymes where they are responsible for the clearance of more than 90% of 
pharmaceutical drugs in the body (Rowland et al. 2013). Several case studies, reports and 
review articles have documented the potential of herbal products to modulate the activity of 
cytochrome P450 enzymes (Breidenbach et al. 2000, Haller and Benowitz 2000, Skalli et al. 
2007, Izzo and Ernst 2009). On the other hand, similar effects on UGT enzymes have not 
been sufficiently studied (Mohamed and Frye 2011a). 
 
A number of findings have investigated the effect of selected herbal medicines on UGT 
enzymes activities (Abidin 2014, Salleh 2014). Each study examined different herbal plants 
(Andrographis paniculata and Curcuma xanthorrhiza) on their inhibitory effects on UGT 
enzymes activities. A concept has been built based on the conclusions of both projects which 
stated: Andrographis paniculata and Curcuma xanthorrhiza will inhibit the metabolism of 
drugs that are primarily metabolized by UGT2B7 – one of the sub-family of UGT enzyme 
(Coffman et al. 1997).  
 
This study attempts to prove the proposed concept of previous findings by assessing the 
metabolic activity of morphine which primarily metabolized by UGT2B7 to be inhibited by 
Andrographis paniculata or Curcuma xanthorrhiza in human in-vitro enzyme system. As 
morphine does not follow any metabolic pathway in human except for glucuronidation by 
UGT2B7, herb-drug interaction between studied plant herbs and morphine is hypothetically 
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to occur. Evaluation through in-vitro inhibition assay using appropriate kinetic model is 
necessary to predict the potentiality of both herbal plants to inhibit the metabolism of 
morphine in human. 
 
Data generated from this study will provide useful information especially for researchers 
with intention to conduct further clinical study in human and for the clinicians that routinely 
deal with patients that are prescribed with morphine to always stay in precaution pertinent to 
morphine interaction side effects. 
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1.2 Herbal Medicines 
1.2.1 Medicinal Plant Herbs 
Plants have played a vital role in maintaining human health and improving their quality of 
life for many centuries. In botanology, herbs refer to seed-producing plant with non-woody 
stem that die at the end of growing season whereas, in the field of herbal medicine, the term 
herb is used loosely to refer not only to seed-producing plant, but also appointed to any parts 
of plant such as fruits, seeds, roots, leaves, flowers and barks that display medicinal 
properties. Herbal plants are commonly used in primary form or occasionally combined into 
mixtures. Pharmacologically active phytoconstituents such as polyphenols, alkaloids, 
flavonoids, terpenoids, anthraquinones, coumarins, saponin, or tannins may present in herbal 
plants. Those constituents are considered to be very useful due to their various biological 
activities including anti-oxidant, anti-inflammatory or anti-cancer properties (Zhou et al. 
2007). 
 
Today, under the bill of Dietary Supplement Health and Education Act 1994 (DSHEA), 
herbs belong to a class of dietary supplement which severely limits the US Food and Drug 
Administration’s (FDA) ability to regulate this class of substances. Unlike pharmaceutical 
drug, medicinal herbs under the bill of DSHEA requires no proof of efficacy, no proof of 
safety, and sets no standards for quality control for any product to be labelled as a dietary 
supplement. Since then, productions of herbal supplements by the industries have become 
viral (Bauer 2003). It is estimated that the global market for herbal products to be worth 
around US$80 to US$100 billion representing an annual growth rate ranging from 5% to 
15% (Gohil and Patel 2007). 
 
In Malaysia, herbal products form the largest group of registered medicines (37.1%), 
compared with prescription drugs (32.2%) and over-the-counter (non-prescription) drugs 
(23.9%) (Ang 2005). From 2000 to 2005, annual sales for herbal products in Malaysia 
increased from US$0.385 to US$1.29 billion (Aziz and Tey 2009). The government has 
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highlighted several core strategies to turn Malaysia into a high income economy by the year 
of 2020. This has led to the introduction of the 12 National Key Economic Areas (NKEA) 
which includes agriculture as one of the main important keys. Under the nation’s agriculture 
NKEA, sixteen entry point project (EPP) have been identified with herbal product ranked as 
the first out of sixteen. In the beginning, five herbal plants namely, Eurycoma longifolia 
(tongkat ali), Orthosiphon stamineus (misai kucing), Andrographis paniculata (hempedu 
bumi), Gynura procumbens (dukung anak) and Labisia pumila (kacip fatimah) were listed as 
the high-value herbal products. Five R&D clusters were established which focus on 
discovery, processing technology, crop production, product standardization and pre-
clinical/clinical studies to further support the EPPs. Initially, the project aimed of producing 
high-value herbal products totalling RM 2.2 billion of the Gross National Income (GNI) 
along with the proposed five herbal plants. At present six more herbal plants have been 
added to the project including Morinda citrifolia (mengkudu), Hibiscus sabdariffa (roselle), 
Zingiber officinale (ginger), Ficus deltoidea (mas cotek), Clinacanthus nutans (belalai gajah) 
and Centella asiatica (pegaga). The market potential of all eleven herbs are being studied at 
current and developed under the 10
th
 Malaysian Plan. With increasing market demand 
globally and locally, there is a need for rigorous scientific examination of herbal medicines 
as it may lead to greater acceptance by mainstream practitioners. 
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1.2.2 Andrographis paniculata 
Andrographis paniculata is an erect annual herb, growing to a height of 30 to 90 cm. The 
leaves are sessile, dark green in colour, glabrous and are lanceolate in shape. The aerial part 
of the plant, including leaves and stems are frequently used as traditional medicine. 
Morphology of the plant parts are shown below (Figure 1.1): 
 
 
 
Figure 1.1 Morphology of Andrographis paniculata plant parts. (a) Herb in pod stage 
with terminal and axilliary panicles, (b) flowering plant with a small opened flower, (c) a 
flower with opened anther and pollen grains, (d) schematic drawing of Andrographis 
paniculata. 
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1.2.2 (a) Taxonomic Hierarchy 
Kingdom : Plantae 
Subkingdom : Viridiplantae 
Infrakingdom : Streptophyta 
Superdivision : Embryophyta 
Division : Tracheophyta 
Subdivision : Spermatophytina 
Class  : Magnoliopsida 
Superorder : Asteranae 
Order  : Lamiales 
Family  : Acanthaceae 
Genus  : Andrographis 
Species  : Andrographis paniculata (Burm. f.) Wall. ex Nees 
 
1.2.2 (b) Phytochemistry of Andrographis paniculata 
Phytochemical analysis of this plant has revealed a myriad species of diterpenoids, 
flavonoids and phytophenols. Diterpenoids are the major phytoconstituents of Andrographis 
paniculata which can be isolated in free and glycoside form. A number of chemical species 
which have been reported includes: andrographolide, andrographiside, neoandrographolide, 
6’-acetylneoandrographiside, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-11,12-
didehydroandrographiside, 14-deoxyandrographolide, 14-deoxyandrographiside, 
andrographanin, andropanoside, isoandrographolide, andrographatoside, andropanolide, 5-
hydroxy-7,8,2’-trimethoxyflavone, 5,2’-dihydroxy-7,8-dimethoxyflavone, 5-dihydroxy-7,8-
dimethoxyflavone, 5-dihydroxy-7,8-dimethoxyflavanone and andrographidine (Kleipool 
1952, Chan et al. 1971, Balmain and Connolly 1973, Smith et al. 1982, Rao et al. 2004, 
Pramanick et al. 2006, Shen et al. 2006, Xu et al. 2010, Lim et al. 2012). 
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Figure 1.2 Selected phytoconstituents of Andrographis paniculata to be used in the 
study: (a) andrographolide and (b) neoandrographolide. 
 
1.2.2 (c) Pharmacological Properties of Andrographis paniculata  
Various reports have documented various biological activities and therapeutic value of 
Andrographis paniculata and its active phytoconstituents. It includes hepatoprotective, 
hypoglycaemic, cardioprotective, anti-inflammatory, immunostimulatory, anti-cancer, anti-
HIV as well as antimalarial properties (Jarukamjorn and Nemoto 2008, Chao and Lin 2010, 
Akbar 2011). 
 
Despite the usefulness and widespread use, information concerning the potential of this plant 
on drug metabolizing enzymes is quite limited. The growing awareness of herb-drug 
interaction has led to a number of studies on the modulatory effect of Andrographis 
paniculata or its phytoconstituents on cytochrome P450 enzyme activity, the so-called main 
drug metabolizing enzymes (Pekthong et al. 2009, Pan, Rashid, et al. 2011, Tan and Lim 
2014). However, the potential of herb-drug interaction on other metabolic pathways beside 
cytochrome P450 still exist and should be given a proper attention. 
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1.2.3 Curcuma xanthorrhiza 
Curcuma xanthorrhiza is a perennial herbaceous plant, growing to a height of 1 m tall. 
Commonly known as Javanese turmeric or temulawak, this herb is one of the family 
members of ginger which originated from Indonesia. It can also be found in Malaysia, Sri 
Lanka, Thailand and Philippines. It is highly branched with alternate leaves arranged in two 
rows. The non-aerial part is made up of yellowish tuberous rhizomes (Figure 1.3): 
 
 
Figure 1.3 Morphology of Curcuma xanthorrhiza plant parts. (a) aerial portion of the 
plant, (b) threefold hermaphrodite flowers, (c) yellowish-orange cylindrical rhizomes, (d) 
schematic drawing of Curcuma xanthorrhiza.  
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1.2.3 (a) Taxonomic Hierarchy  
Kingdom : Plantae 
Subkingdom : Viridiplantae 
Infrakingdom : Streptophyta 
Superdivision : Embryophyta 
Division : Tracheophyta 
Subdivision : Spermatophytina 
Class  : Magnoliopsida 
Superorder : Lilianae 
Order  : Zingiberales 
Family  : Zingiberaceae 
Genus  : Curcuma 
Species  : Curcuma xanthorrhiza Roxb. 
 
1.2.3 (b) Phytochemistry of Curcuma xanthorrhiza 
Investigation of phytochemical content of this plant has shown that Curcuma xanthorrhiza 
contains various classes of phytocompounds. It includes curcuminoids (mixture of curcumin, 
monodemethoxycurcumin, bis-demethoxycurcumin), sesquiterpenes (β-curcumene, ar-
curcumene, bisabolane, lactone germacrone), flavonoids (catechin, epicatechin, quercetin, 
myricertin, kaemferol, apigenin, luteolin, naringenin), camphor and xanthorrhizol (Zwaving 
and Bos 1992, Jarikasem et al. 2003, Ruslay et al. 2007, Tsai et al. 2011, Jantan et al. 2012). 
 
Evaluation of the presences of xanthorrhizol and the absence of bisdemethoxycurcumin are 
the best ways to distinguish between Curcuma xanthorrhiza (Javanese turmeric) and 
Curcuma longa (turmeric) (Jantan et al. 2012). 
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Figure 1.4 Selected phytoconstituents of Curcuma xanthorrhiza to be used in the study: 
(a) xanthorrhizol and (b) curcumin. 
 
1.2.3 (c) Pharmacological Properties of Curcuma xanthorrhiza  
The rhizomes of this plant have been traditionally used to treat various diseases including 
liver disorder, gallstone, jaundice and to promote the flow of biliary secretion. Apart from 
medicinal purposes, Curcuma xanthorrhiza is also commonly used in food making (Ismail et 
al. 2005, Cheah et al. 2006, Hatcher et al. 2008, Cheah et al. 2009, Kang et al. 2009, Kim et 
al. 2012). 
 
The principal components of Curcuma xanthorrhiza are xanthorrhizol and curcumin. The 
two components possess a wide range of pharmacodynamic values which have been shown 
capable to overlap to produce synergistic therapeutic effect (Cheah et al. 2009). Curcumin 
also is one of the main constituent of Curcuma longa. For that reason, it had undergoes 
various pharmacokinetic study where it has been shown that curcumin demonstrates poor 
systemic bioavailability due to rapid metabolism in the gut and liver (Vareed et al. 2008). 
Unlike curcumin, xanthorrhizol having much less attention concerning to it pharmacokinetic 
nature. At present, here are no bioavailability data of xanthorrhizol as well as information on 
its metabolic pathway particularly in mammals. 
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1.3 Drug Metabolism 
Drug metabolism is a biochemical reaction of pharmaceutical substances catalyzed by a 
group of specialized enzymes, notable to many as drug metabolizing enzymes. It covers 
three phases in which phase I involves the redox (reduction and oxidation) reaction of the 
substances while Phase II performs chemical conjugation process and phase III is the 
involvement of membrane transporter on the excretion of drugs and their metabolites 
(Changjiang et al. 2005). 
 
1.3.1 Drug Metabolizing Enzymes 
Drug metabolizing enzymes are diverse classes of proteins that are responsible for 
metabolizing a myriad species of pharmaceutical substances. Metabolic biotransformation of 
drugs by these enzymes forms a more hydrophilic metabolite which not only leads to the 
deactivation of the pharmacologically active drugs but also enhancing the excretion process 
in the body. As a result, the functional homeostasis of the cell is preserved in the face of 
chemical challenges (Penner et al. 2012).  
 
Phase I drug metabolizing enzymes catalyze the modification of chemical functional groups 
within a molecule to improve its hydrophilicity. Such reactions are catalyzed by a number of 
protein enzymes which include cytochrome P450s, aldehyde oxidases, monoamine oxidases 
and flavin-containing monooxygenases (Iyanagi 2007). 
 
Phase II drug metabolizing enzymes carry out chemical conjugation process where it 
involved the transfer of a hydrophilic moiety entity onto a substrate which greatly enhance 
its water solubility nature as compared to phase I. Phase II biotransformation reactions 
include sulfonation, glucuronidation or glutathione conjugation. Enzymes that involved in 
phase II stage are the sulfotransferases, Uridine 5’-diphospho-glucuronosyl transferases and 
glutathione S-transferases (Petra and Michal 2012). 
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1.3.2 UGT Enzymes 
Uridine 5’-diphospho-glucuronosyltransferases (UGTs) are superfamily of protein enzymes 
that are responsible for metabolism of endobiotics and xenobiotics in many organisms 
including humans. UGT enzymes play a major role in catalyzing a conjugation process 
known as glucuronidation. During glucuronidation, a glucose-derived moiety, glucuronic 
acid is conjugated to a suitable functional site (hydroxyl, carboxyl, carbonyl, sulfhydryl, and 
amine) on a substrate modulated by UGT proteins (Figure 1.5). Generally, this metabolic 
process generates a highly soluble inactive metabolite which renders excretion process in the 
body.  
 
 
 
Figure 1.5 Glucuronic acid conjugation of a substrate catalyzed by UGT enzymes 
producing a highly soluble metabolite. 
 
UGT enzymes display a broad and overlapping substrate specificities, which are common 
features for drug-metabolizing enzymes (Court et al. 2005). Human UGTs are divided into 
two families, UGT1 (1A1, 1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9, 1A10) and UGT2 (2A1, 
2A3, 2B4, 2B7, 2B10, 2B11, 2B15, 2B28). These two families originated from two 
separated genes located on chromosome 2q37 and 4q13 which encode a number of different 
proteins yet, still perform the same glucuronidation function (Mackenzie et al. 2005). 
Inhibition of UGT metabolic activities may cause serious threats especially in metabolizing 
environmental toxicants or native endobiotics for example bilirubin, a by-product of 
haemoglobin catabolism which can only be removed via conjugation with glucuronic acid 
(Desai et al. 2003).  
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1.3.3 Latency of Microsomal UGTs 
UGT proteins are believed to be localized within the luminal wall of endoplasmic reticulum 
(Figure 1.6).  
 
 
Figure 1.6 Schematic representation of UGT protein (UGT1A1) within the luminal wall 
of endoplasmic reticulum (ER). Almost the entire polypeptide chain resides in the lumen, 
except for the COOH-terminus. (Rouleau et al. 2013). 
 
It has been suggested that the existence of active transporters in living system is vital in 
order to translocate the substrate from cytosolic space into the lumen where UGT active site 
is located. Without active transporter, glucuronidation reaction will become latent and slower 
than it should be. The latency seen in microsomal glucuronidation is thought to be due to the 
presence of a membrane obstructing the free access of substrate to the enzyme. Fully 
functional transporters are assumed to exist in hepatocytes but optimal microsomal 
glucuronidation requires an activation step which disrupts the membrane thereby permitting 
the flow of substrate between the cytosol and the lumen (Ishii et al. 2012). Several treatments 
activate the microsomal glucuronidation reaction particularly detergents, physical disruption, 
sonication and the pore-forming agent alamethicin. In absence of activation, microsomal 
15 
 
UGT remains in a latent state. Incubation of microsomal UGT with alamethicin activates the 
microsomal glucuronidation activity by 10 folds higher compared to the untreated 
microsomes. It was discovered that alamethicin embedded itself in cluster on the 
endoplasmic reticulum membrane to form a well-define pore (Figure 1.7). The microsomal 
glucuronidation is also stimulated by Mg
2+
 and hence incubation are routinely supplemented 
with MgCl2 (Pang et al. 2009). 
 
 
 
Figure 1.7 Schematic of alamethicin pores in membrane bilayer. Each pore comprises 
eight units of alamethicin align in barrel-stave fashion. (He et al. 1995). 
 
1.3.4 In-vitro Model 
Since liver plays a major role in drug metabolism, there are many models that have been 
built to imitate the organ’s metabolic process. There are various in-vitro tools in studying 
drug metabolism where this study has decided to focus on two models that commonly used 
by researchers around the world; the recombinant expressed protein and human liver 
microsomes. 
 
Human drug metabolizing enzymes have been genetically engineered from various 
recombinant expression systems including bacteria, insect or other mammalian cell systems. 
The isolated protein of the expression system provides an important functional assay for 
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single protein species worth for the study of various fields of drug metabolism (Plant 2004). 
The baculovirus-insect cell expression system is the most common recombinant model used 
today due to its absence or lack of cytochrome P450 and UGT protein species. Taking 
advantage of that characteristic, the insect cells can be transfected with cDNA of human 
UGTs to express desired protein species. The major benefit of this model is its simplicity and 
allowing the study of specific enzyme separately. The major drawback of recombinant 
protein is the difference in the metabolic activity of enzyme per unit of microsomal protein 
compared to that in human liver microsomes (Baranczewski et al. 2006). 
 
Human liver microsome is one of the main sources of drug metabolizing enzymes. 
Microsomes are not ordinarily present in living cell. It is a fraction of cellular debris which is 
produced in the laboratory through centrifugation technique. Microsomes can be separated 
out via differential centrifugation. Most organelles will be sediment-out at 10 000g while 
soluble enzymes and fragmented endoplasmic reticulum remain in the supernatant fraction. 
At 100 000g, endoplasmic reticulum will be precipitated out leaving soluble enzymes to 
remain in the solution. The resulting pellet is the microsomal fraction which contain the 
cytochrome P450 and the UGTs. However, the addition of exogenous co-factors or co-
substrate such as NADPH or UDPGA is necessary to activate the enzymes. It is said that, 
liver microsomes are one of the best characterized in-vitro tool for drug metabolism studies 
beside being low in cost and the ease of handling the system (Brandon et al. 2003). 
 
1.3.5 Drug Interaction through Glucuronidation 
Drug Interaction is a condition whereby a substance affects the activity of a drug when both 
are administered together. Drug interaction often involved the inhibition of drug 
metabolizing enzyme activity, resulting in increased systemic exposure and subsequent 
adverse effect. In other cases, induction of drug metabolizing enzyme expression resulted in 
reduced systemic exposure leading to the risk of loss of efficacy. Like many enzymes, UGTs 
also have the potential to be inhibited which may affect the glucuronidation of substrates 
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catalyzed by these enzymes. Therefore, there is a potential for consequences that affecting 
clinical efficacy in UGT-mediated drug interaction. It gets worst when the metabolism of a 
substance exclusively follows glucuronidation pathway like zidovudine, codeine and 
morphine which can result in a significant increase of drugs exposure upon inhibition. 
Similarly important, since many phytocompounds are also substrates for UGTs, herb-drug 
interactions via glucuronidation pathway is always possible and should not be neglected 
when studying drug interactions (Mohamed and Frye 2011a). 
 
1.4 Enzyme Kinetics 
Enzyme kinetics is a way to learn and predict the behaviour of enzymes through 
mathematical relationship. It has become an important part in ADME (absorption, 
distribution, metabolism, excretion) studies where estimation of various kinetic parameters 
such as Vmax, Km and Ki are carried out in determining the degree of involvement of a 
particular enzyme in presence of substrate and inhibitor. This ultimately leads to the 
extrapolation of data from in-vitro to in-vivo model to predict the likelihood of a factor to 
occur in a real system supplemented by laboratory data. 
 
1.4.1 Michaelis-Menten Kinetics 
In 1913, German biochemist Leonor Michaelis and Canadian physician Maud Menten have 
proposed a mathematical relationship between enzyme and its substrate (Michaelis and 
Menten 1913). It involves a substrate [S] binds to an enzyme [E] forming a transition 
complex [ES] and later on converted into product [P] and enzyme [E] in reversible fashion: 
 
 
[E] + [S] 
k1
⇌
k2
 [ES] 
k3
⇌
k4
 [E] + [P] 
(Eq. 1. 1) 
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It was during 1925, an improvement of Michaelis-Menten kinetics was proposed by Briggs 
and Haldane (1925) where the formation of [P] was assumed to be purely forward reaction 
and the introduction of quasi-steady state to simplify the equation as shown below: 
 
 
[E] + [S] 
k1
⇌
k2
 [ES] 
k3
⇀ [E] + [P] 
(Eq. 1.2) 
 
The quasi-steady state assumes the concentration of enzyme-substrate complex [ES] is 
unchanged at the early stage of reaction which can be expressed as, d[ES] = 0 (Figure 1.8). 
 
 
Figure 1.8 Change in concentration over time of enzyme [E], substrate [S], enzyme-
substrate complex [ES] and product [P]. The quasi steady state assumes the formation of 
[ES] to be constant and d[ES] = 0 throughout its effect. 
 
From equation (Eq. 1.2), a number of rate law equations applying the law of mass action can 
be proposed as shown below: 
 
[ES]
Time
C
o
n
c
e
n
tr
a
ti
o
n
[S] [P]
[E]
Quasi Steady State
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d[E]
dt
= −k1[E][S] + k2[ES] + k3[ES] (Eq. 1. 3) 
  
d[S]
dt
= −k1[E][S] + k2[ES] (Eq. 1.4) 
  
d[P]
dt
= k3[ES] (Eq. 1.5) 
  
d[ES]
dt
= k1[E][S] − k2[ES] − k3[ES] (Eq. 1.6) 
 
The latter equation (Eq. 1.6) describes the rate of change of the [ES] complex. At initial of 
reaction, [ES] concentration will rapidly approach the quasi-steady state that is after initial 
burst phase. Its concentration will not change significantly until a significant amount of 
substrate has been consumed. d[ES] can be assumed as 0 as long as kinetic measurement is 
carried out under quasi-steady state. 
When d[ES] = 0, 
 
d[ES]
dt
= 0 
(Eq. 1.7) 
  
0 = k1[E][S] − k2[ES] − k3[ES] (Eq. 1.8) 
  
k1[E][S] = k2[ES] + k3[ES] (Eq. 1.9) 
  
k1[E][S] = (k2 + k3)[ES] (Eq. 1.10) 
  
[E][S] = (
k2 + k3
k1
) [ES] 
(Eq. 1.11) 
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Michaelis-Menten Constant, Km =
k2+k3
k1
 therefore, 
[E][S] = Km[ES] (Eq. 1.12) 
 
Total enzyme concentration [E]t is the sum between free enzyme [E] and enzyme-substrate 
complex [ES] where [E]t = [E] + [ES]. 
Hence, [E] = [E]t − [ES] 
 
([E]t − [ES])[S] = Km[ES] (Eq. 1.13) 
  
[E]t[S] − [ES][S] = Km[ES] (Eq. 1.14) 
  
[E]t[S] = Km[ES] + [ES][S] = [ES](Km + [S]) (Eq. 1.15) 
  
[ES] =
[E]t[S]
Km + [S]
 
(Eq. 1.16) 
 
Formation rate of product [P] is the measured reaction velocity, 𝑣 =
d[P]
dt
= k3[ES] 
 
[ES] =
𝑣
k3
=
[E]t[S]
Km + [S]
 
(Eq. 1.17) 
  
𝑣 =
k3[E]t[S]
Km + [S]
 
(Eq. 1.18) 
 
Since Vmax is the reaction velocity during all enzymes is saturated with its substrate [E]t, 
Vmax = k3[E]t 
Therefore, 
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𝑣 =
Vmax ∙ [S]
Km + [S]
 
(Eq. 1.19) 
 
The relationship above is the well-known Michaelis-Menten equation where 𝑣 is the reaction 
velocity (rate of product formation), [S] is the substrate concentration, Vmax is the maximal 
velocity of the reaction and Km is the Michaelis-Menten constant where it represent the ratio 
of equilibrium constants of [ES] formation (k1) and its dissociation (k2 and k3). Km also 
represent the affinity of substrate toward its enzyme as small Km value indicates a larger k1 
value which means forward reaction of [E]+[S] is favourable. 
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Figure 1.9 Representative hyperbolic plot of a reaction following Michaelis-Menten 
Kinetics. 
 
A plot of reaction velocity, 𝑣 as a function of the substrate concentration, [S] as depicted 
above shows that the maximal velocity Vmax is approached asymptotically for an enzyme 
that obeys Michaelis-Menten kinetics (Figure 1.9). This is due to the saturation of enzyme at 
high substrate concentrations provided the amount of enzyme is fixed during the reaction. 
 
1.4.2 Initial Rate of Reaction 
In kinetic studies, it is common practice to perform measurement of reactant(s) and/or 
product(s) at initial rate as it excludes the contribution of reagents while at excess. In 
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perspective of Michaelis-Menten Kinetics, the equation assumes no product reversibility 
(purely forward reaction) and formation of enzyme-substrate complex [ES] occurs at quasi-
steady state condition. Both assumptions can be satisfied only if measurements are being 
made during the stage of initial rate (formation of product less than 10%). Incubation time 
and protein content are the two parameters that can be optimized to achieve the state of 
initial rate. It is of little importance to prioritize any of the two as long the formation of 
product is still less than 10% but both parameters do have several effects to one another 
especially in terms of speed of reaction. To achieve 10% product formation in short amount 
of time, a large amount of protein (enzyme) is required which translate to faster catalytic 
activity whereas small amount of protein will lengthen the time of reaction in order to 
accomplish the same task. 
 
1.4.3 Linear transformation of Michaelis-Menten Kinetics 
Since the relationship between the independent variable 𝑣 and dependent variable [S] is non-
linear, it has long been customary to facilitate estimation of the two variables by linearized 
the relationship which was first proposed by Lineweaver and Burk (1934): 
 
Taking the reciprocal of both sides of Michaelis-Menten Equation (Eq. 1.19), 
 
1
𝑣
=
Km + [S]
Vmax ∙ [S]
 
(Eq. 1.20) 
  
1
𝑣
=
Km + [S]
Vmax ∙ [S]
=
Km
Vmax ∙ [S]
+
[S]
Vmax ∙ [S]
=
Km
Vmax
∙
1
[S]
+
1
Vmax
 
(Eq. 1.21) 
  
Hence, the Lineweaver-Burk derivation, 
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1
𝑣
= (
Km
Vmax
) ∙
1
[S]
+
1
Vmax
 
(Eq. 1.22) 
 
Lineweaver-Burk plot or double-reciprocal plot (Figure 1.10) is widely used as a simple 
graphical method to determine important terms in enzyme kinetics, such as Km and Vmax. The 
𝑦-intercept of Lineweaver-Burk plot is equivalent to the inverse of Vmax while the 𝑥-intercept 
represent -1/Km.  
0
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Figure 1.10 Double reciprocal plot of reaction velocity, 𝑣 as a function of substrate 
concentration, [S] yielding a linearized Michaelis-Menten relationship. 
 
1.4.4 Enzyme Inhibition 
A number of substances may cause a reduction of an enzyme catalytic process causing 
inhibition. Loss of activity may either be reversible or irreversible. Reversible inhibitor 
interacts with its target enzyme through simple, reversible binding mechanism where activity 
may be restored by the removal of inhibitor. Irreversible inhibitor on the other hand 
deactivates the enzyme where the loss of activity cannot be recovered during the timescale of 
interest. Heavy metal ions (e.g. lead or mercury) usually cause such irreversible inhibition by 
binding strongly to the amino acid backbone (Chaplin and Bucke 1990). For most enzyme-
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catalyzed processes, the occurrence of reversible inhibition is more common and it is 
generally discussed in term of a simple expansion of Michaelis-Menten reaction scheme: 
 
 
[E] + [S] ⇌ [ES] ⇀ [E] + [P]
+ +
[I] [I]
⥮ ⥮
[EI] ⇌ [ESI]
 
(Eq. 1.23) 
 
Where [I] represents the inhibitor, [EI] represents the enzyme-inhibitor complex and [ESI] 
represent the enzyme-substrate-inhibitor complex. Reversible inhibitor may be competitive, 
uncompetitive, mixed or non-competitive depending upon its point of entry into the enzyme. 
 
1.4.4 (a) Competitive-Type Inhibition 
Competitive inhibition occurs when both substrate and inhibitor compete for the same active 
site on the enzyme. Competitive type is most noticeable at low substrate concentration but 
can be overcome at high substrate concentration as the Vmax remains unaffected. 
 
From the expansion of Michaelis-Menten reaction scheme (Eq. 1.23), competitive inhibition 
will involve additional relationship between enzyme and inhibitor with its respective 
equilibrium constants: 
 
[E] + [I]
k4
⇌
k5
[EI] 
(Eq. 1.24) 
 
From (Eq. 1.24), an additional rate law can be proposed, 
 
d[EI]
dt
= k4[E][I] − k5[EI] (Eq. 1.25) 
 
